Ophthalmology

Top Story

Valeant, EyeGate enter licensing agreement

February 21, 2017

Valeant Pharmaceuticals has entered into a licensing agreement with EyeGate Pharmaceuticals regarding the EyeGate II delivery system and EGP-437 combination product candidate for postoperative pain and inflammation, according to a press release from the companies.

Through the agreement, Valeant will have worldwide commercial and manufacturing rights for the EyeGate II delivery system and EGP-437, while EyeGate will maintain development of the delivery system in the U.S. Valeant can develop the system outside of the U.S.

Blog

BLOG: The goblet cell non-controversy

February 21, 2017
One of the neat things about being on the Rubber Chicken Dinner Circuit of industry-sponsored talks is that you get to hear firsthand what it is that your peers are…
Meeting News

Anti-VEGF therapy may not have impact on cataract surgery outcomes in DME patients

February 21, 2017
MIAMI — Anti-VEGF therapy for the treatment of diabetic macular edema does not have a negative impact on patients who undergo cataract surgery, according to a…
Meeting NewsFrom OSN EuropeVideo

VIDEO: Measuring keratoconus progression still challenging

February 21, 2017
MAASTRICHT, Netherlands – At the European Society of Cataract and Refractive Surgeons winter meeting, David Touboul, MD, PhD, speaks about

Glaukos completes enrollment in iStent Supra trial

February 20, 2017
Enrollment in the investigational device exemption trial for the iStent Supra for treatment of patients with open-angle glaucoma and cataracts has been completed…
More News Headlines »
Clinical Science

Functional and Morphological Evaluation of Traumatized Eyes With Berlin's Edema Affecting the Macula Using mfERG, Microperimetry, and SD-OCT

Ophthalmic Surgery, Lasers and Imaging Retina, February 2017, Volume 48 Issue 2
To describe the structural and functional changes that occur in traumatic Berlin's edema involving the macula through…
More »
CME

Current Insights: Applying New Data to Optimize Treatment of Diabetic Retinal Disease

This activity is supported by an educational grant from Bausch + Lomb.

Glaucoma is currently the second leading cause of blindness throughout the world. The goal of glaucoma treatment is to…
More »
Featured
Hawaiian Eye/Retina Meeting

Hawaiian Eye/Retina Meeting

Video From OSN Europe
Meeting News

VIDEO: Dealing with refractive error after multifocal IOL implantation

February 15, 2017
More »
Advertisement
Advertisement